Gyre Therapeutics, Inc. (GYRE) — Dilution Risk Analysis
Current Snapshot
Gyre Therapeutics, Inc. (GYRE) has a DilutionWatch score of 40/10 and is classified as MEDIUM risk. The score date in the source data is 2026-10-03T03:45:52.527348.
This page is assembled from sourced share-structure, market-data, SEC-filing, and DilutionWatch fields. Missing values are left blank rather than estimated.
Dilution Risk Score
Score: 40/10 Source (as of 2026-10-03T03:45:52.527348)
Recent SEC Filings
Recent filing forms in the source payload: FORM 4 2, XBRL 2, 8-K 2, 4 2.
| Form | Filed | Accession |
|---|---|---|
| Form 4 | 2026-08-03 | 0001140361-26-031326|0002060874|2026-08-03|A|40000 |
| Form 4 | 2026-08-03 | 0001140361-26-031324|0002060862|2026-08-03|A|40000 |
| xbrl | 2026-06-30 | xbrl-3596-xbrl_warrant |
| 8-K | 2026-05-04 | 0001140361-26-018716 |
| 8-K | 2026-03-02 | 0001140361-26-007249 |
| 4 | 2026-01-09 | 0001140361-26-000831 |
| 4 | 2026-01-09 | 0001140361-26-000832 |
| xbrl | 2018-12-31 | xbrl-3596-xbrl_convertible |
Dilution Risk Drivers
| Driver | Stored Value | Source |
|---|---|---|
| Cash runway | 999 months | Source |
| Three-year share count growth | 193.62% | Source |
DilutionWatch Analysis
- Risk Level
- MEDIUM (Score: 40/10) Source
- Cash Runway
- 999 months Source
- Share Count Growth (3-Year)
- 193.62% Source
What This Page Does Not Estimate
DilutionWatch does not infer missing cash runway, authorized share count, ATM capacity, shelf capacity, or share-growth values on this page. A blank field means the current source payload did not provide a usable value with provenance.
Scores and classifications are shown only when supplied by the DilutionWatch data layer. SEC filing rows link to their source accession when a filing URL is available.